Mayo Clin Proc Innov Qual Outcomes
Objective: To systematically review the literature and estimate the risk of Chloroquine (CQ) and hydroxychloroquine (HCQ) cardiac toxicity in COVID-19 patients.
Methods: We searched multiple data sources including PubMed/MEDLINE, Ovid Embase, Ovid EBM Reviews, Scopus, and Web of Science, and medrxiv.org from November 2019 through May 27, 2020. We included studies that enrolled COVID-19 patients treated with CQ or HCQ, with or without azithromycin and reported on cardiac toxicities. We performed a meta-analysis using the arcsine transformation of the different incidences.
Results: A total of 19 studies with a total of 5652 patients were included. The pooled incidence of TdP arrhythmia or VT or cardiac arrest was 3 per 1000, 95% CI (0-21), I
Conclusions: Treatment of COVID-19 patients with CQ or HCQ is associated with a significant risk of drug-induced QT prolongation and relatively higher incidence of TdP/VT/cardiac arrest. Therefore, these agents should not be used routinely in the management of COVID-19 disease. COVID-19 patients who are treated with antimalarials for other indications should be adequately monitored.
Tleyjeh, Imad M; Kashour, Zakariya; AlDosary, Oweida; Riaz, Muhammad; Tlayjeh, Haytham; Garbati, Musa A; Tleyjeh, Rana; Al-Mallah, Mouaz H; Sohail, M Rizwan; Gerberi, Dana; Bin Abdulhak, Aref A; Giudicessi, John R; Ackerman, Michael J; and Kashour, Tarek, "The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis." (2020). Articles, Abstracts, and Reports. 3980.